OrthoAccel® Technologies Committed to Plans for Positioning The United Kingdom as a Key Strategic Market for New Orthodontic Technology

Houston, TX, September 15, 2010
OrthoAccel® Technologies, Inc. has announced commercial plans for the United Kingdom that entail considerable business activity and economic impact. Last year, the Company hired a Director of Sales based in Wales. Recently, a full-market UK release of the AcceleDent™ System was reported. In conjunction with this product introduction at the British Orthodontic Conference, OrthoAccel® has publicized plans to host a private lecture and reception to provide scientific data and education to doctors on this new technology that shortens orthodontic treatment time.

AcceleDent™ is a simple, removable dental device that patients place in the mouth for twenty minutes daily. It produces a gentle vibrational force which enhances the pressure applied by braces. AcceleDent™ has been clinically proven to safely speed up orthodontic tooth movement. The product is hands-free and allows the user flexibility to carry out most routine tasks during use.

Mike Kaufman, VP of Marketing and Business Development at OrthoAccel® explained, “We really made every effort to develop an easy-to-use device that would fit into a patient’s daily routine with no trouble or inconvenience.”

And patients agree that the Company has accomplished just that.

“I am usually watching television or reading journals whilst using AcceleDent™,” reported one adult patient, who is a physician and under the care of Dr Asif Chatoo, a London-based orthodontic specialist. She continued, “I am extremely pleased with my orthodontic treatment and feel that AcceleDent™ has helped me achieve the cosmetic result I hoped for in a short time period. I absolutely would recommend it to someone undergoing orthodontic treatment.”

So now that AcceleDent™, which was made available last year to a select group of orthodontic specialists, will be available to all orthodontists in the United Kingdom, what comes next?

“We view the UK as a very important strategic market,” shared Mike Lowe, CEO of OrthoAccel®. “We anticipate continued investment in a country that we consider a critical entry point into the EU Region. In addition to our sales and marketing investment, we are currently conducting analysis as to the most effective way of establishing a corporate presence and true legal entity in the UK. Since our founding in 2007, and through our development stage, we have created a number of jobs here in the states, and the prospect of crafting economic value in other parts of the world as well is very exciting.”

That value, however, is not limited to commercialization.

“We are also currently in the process of partnering with a renowned dental hospital to conduct a clinical trial in the UK as early as 2011,” added Kaufman. “We intend to build the reputation of AcceleDent™ and our company OrthoAccel® on clinical outcome studies that add to the body of evidence based medicine.”

OrthoAccel® is anticipating the conclusion of another US clinical trial at the UT Health Science Center in San Antonio with a target completion date later in 2010.
About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the AcceleDent™ System
AcceleDent™ represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent™ is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com

Media Contact Michael K. Lowe, CEO +1 (832) 631-1659